Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal

Vertex acquisition terms and what they mean for Crinetics shareholders

Crinetics Pharmaceuticals (CRNX) stock is in focus after Vertex Pharmaceuticals agreed to acquire the company in a cash deal valuing Crinetics at about $10b, or $85 per share.

The transaction, announced on July 6, 2026, would make Crinetics a wholly owned subsidiary of Vertex if it closes. The financing would be supported by a mix of cash, debt, and committed bridge funding.

See our latest analysis for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals’ share price has surged in recent months, with a 30-day share price return of 142.85% and a 90-day share price return of 110.49%. The 1-year total shareholder return of 162.99% and 3-year total shareholder return above 3x suggest strong momentum building into the Vertex acquisition news.

If this kind of deal activity has your attention, it may be a good moment to look at other healthcare-focused opportunities and see what stands out in the 40 healthcare AI stocks.

Crinetics now trades just below the US$85 cash offer and slightly above the average analyst target of US$82.50. This raises a simple question: how much upside, if any, is left for shareholders at these levels?

Most Popular Narrative: 7% Undervalued

The most followed narrative currently places Crinetics Pharmaceuticals’ fair value at $90 per share, modestly above the last close at $83.71, which helps explain why some investors still see residual value beyond the $85 Vertex offer.

The assumed bullish price target for Crinetics Pharmaceuticals is $90.0, which represents up to two standard deviations above the consensus price target of $82.5. This valuation is based on what can be assumed as the expectations of Crinetics Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.

Read the complete narrative.

Want to understand why this narrative still points above the deal price? It leans on rapid revenue expansion, margin repair, and a premium future earnings multiple. Curious how those moving parts add up to that $90 figure.

Result: Fair Value of $90 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Crinetics Pharmaceuticals narrative could be knocked off course if the acromegaly opportunity proves smaller than modeled or if payer policies tighten access.

Find out about the key risks to this Crinetics Pharmaceuticals narrative.

Next Steps

With Crinetics Pharmaceuticals presenting both risks that worry investors and rewards that keep them optimistic, it makes sense to move quickly, review the details, and weigh the evidence for yourself using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Crinetics Pharmaceuticals?

If the Crinetics Pharmaceuticals story has sharpened your focus, do not stop here. Use the Simply Wall St Screener to spot other stocks that fit your style.

• Target potential value opportunities by reviewing companies that appear mispriced on quality and fundamentals in the 44 high quality undervalued stocks.
• Prioritise resilience by checking stocks with more robust financial profiles using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for lesser known stories that still meet strict quality filters with the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com